TherapeuticsMD enters agreements to license products to Mayne Pharma

• TherapeuticsMD (NASDAQ:TXMD) has entered into pact to license its products to an affiliate of Mayne Pharma Group Limited for commercialization in the United States.
• In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products, including inventory.
• TXMD to receive ~$153.1M in consideration at closing (including ~$13.1M for acquired net working capital), up to ~$42.6M in minimum royalty payments, and up to $30.0M in additional milestone payments.
• Mayne Pharma gains exclusive U.S. commercialization rights for TXMD’s products.
• The deal allows TXMD to recapitalize and transform into a pharmaceutical royalty company.
• Upon closure, Mayne Pharma will be responsible for development, regulatory filings, manufacturing, and commercialization of the Products.
• The company will retain its existing licensing agreements with Knight Therapeutics and Theramex HQ UK Limited.

• The deal is not subject to any financing conditions and is expected to close at the end of 2022.